Belite Bio annual stock-based compensation
2020
2021
2022
2023
2024
2025
Belite Bio Stock-Based Compensation Growth & History (BLTE)
Belite Bio's stock-based compensation was $38.9M for fiscal 2025.
View full Belite Bio company overviewBelite Bio annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $38.9M | $29.9M | +333.06% |
| 2024 | 2024-12-31 | $9.0M | $5.2M | +135.08% |
| 2023 | 2023-12-31 | $3.8M | $2.3M | +157.79% |
| 2022 | 2022-12-31 | $1.5M | −$47,000 | −3.07% |
| 2021 | 2021-12-31 | $1.5M | $167,000 | +12.25% |
| 2020 | 2020-12-31 | $1.4M | — | — |
Belite Bio quarterly stock-based compensation
Q4.24
Q4.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $11.7M | $7.5M | +178.57% |
| Q4 2024 | 2024-12-31 | $4.2M | — | — |
Belite Bio stock-based compensation trends
Over the last five fiscal years, Belite Bio's stock-based compensation increased from $1.4M to $38.9M, a change of $37.6M. The latest reported quarter, Q4 2025, shows $11.7M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Belite Bio source filings ↗